Pacific Ethanol is a producer and marketer of low-carbon renewable fuels. The company's segments include: Production Segment and Marketing Segment. In its Production Segment, the company produces ethanol, specialty alcohols and co-products at its production facilities. The company produces ethanol co-products at its production facilities such as wet distillers grains, dried distillers grains with solubles, wet and dry corn gluten feed, corn gluten meal, and corn oil. In its Marketing Segment, the company markets ethanol, specialty alcohols and co-products produced by its facilities and markets ethanol produced by third parties. The company also markets its distillers grains and other feed co-products to dairies and feedlots.

Cardiovascular Systems is a medical technology company. The company has developed an orbital atherectomy systems (OAS) for both peripheral and coronary commercial applications. The primary base of the company's business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. The company's products include its coronary arterial disease (CAD) product, the Diamondback 360 Coronary OAS, which is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.

CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company's primary focus is on the development of its key product candidate, Neutrolin

Fluent provides digital marketing services. The company primarily performs customer acquisition services by operating digital marketing campaigns, through which the company connects its advertiser clients with consumers. The company delivers data and performance-based marketing executions to its clients, across a range of industries, including Financial Services, Retail and Consumer, Media and Entertainment, Staffing and Recruitment and Marketing Services. The company provides performance marketing solutions to its clients based on their desired outcomes, or specific actions in their marketing funnels, including submission of a registration form, app installation or a completed transaction.

Franklin Financial Network is a financial holding company. Through its wholly owned bank subsidiary, Franklin Synergy Bank, the company provides a range of banking and related financial services which focus on service to small businesses, corporate entities, local governments and individuals. The company's line of financial products include commercial banking, consumer banking, mortgage loans, deposits, retirement planning, financial planning, investment services, and insurance products through its wealth management department. The company operates through branches in WWilliamson, Davidson, and Rutherford counties within the Nashville metropolitan area.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Kearny Financial is the holding company for Kearny Bank (the Bank), a nonmember New Jersey stock savings bank. The Bank is engaged in the business of accepting deposits from the general public in New Jersey and New York and using these deposits, together with other funds, to originate or purchase loans for its portfolio and invest in securities. The company's loan portfolio is comprised of loans collateralized by commercial and residential real estate augmented by secured and unsecured loans to businesses and consumers. The company's deposit products include interest-bearing and non-interest-bearing checking accounts, money market deposit accounts, savings accounts and certificates of deposit accounts.

Navient is a provider of education loan management and business processing solutions. The company's segments include: Federal Education Loans, in which the company holds and acquires Federal Family Education Loan Program Loans and performs servicing and asset recovery services on its own loan portfolio, federal education loans owned by the United States Department of Education and other institutions; Consumer Lending, in which the company holds, originates and acquires consumer loans and performs servicing activities on its own education loan portfolio; and Business Processing, which performs revenue cycle management and business processing services for non-education related government and healthcare clients.

NGM Biopharmaceuticals is a biopharmaceutical company. The company is focused on the following programs: Aldafermin, which is for the treatment of non-alcoholic steatohepatitis (NASH); NGM313 (MK-3655), which is for the treatment of NASH and type 2 diabetes; NGM120, which is designed to block the effects of elevated growth differentiation factor 15 levels on cancer anorexia/cachexia syndrome, and, possibly, tumors; NGM217, which is designed to restore pancreatic islet function and increase insulin production in patients with diabetes; NGM621, which is designed to decrease levels of this protein implicated in the dry form of AMD; and NGM395, which is for the treatment of metabolic syndrome.

Provention Bio is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. The company's principal product candidates include: PRV-031 (teplizumab, anti-CD3 mAb) for the interception of type 1 diabetes; PRV-015 (anti-IL-15 mAb) for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 (oral CSF-1R inhibitor) for the treatment of Crohn's disease; PRV-300 (anti-TLR3 mAb) for the treatment of ulcerative colitis; and PRV-3279 (humanized anti-CD32B and CD79B bispecific) for the treatment of lupus.

Regional Management is a consumer finance company that provides installment loan products primarily to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. Most of the company's loan products are secured, and each is structured on a fixed-rate, fixed-term basis with fully amortizing equal monthly installment payments, repayable at any time without penalty. The company sources its loans through its multiple channel platform, which includes its branches, digital partners, retailers, and its consumer website. The company's products include small, large, and retail installment loans. The company's small loans and large loans are its primary loan products.

Unifi manufactures and sells recycled and synthetic products made from polyester and nylon primarily to other yarn manufacturers and knitters and weavers that produce yarn and/or fabric for the apparel, hosiery, home furnishings, automotive, industrial and other end-use markets. The company has four segments: Polyester, which sells polyester-based products to other yarn manufacturers, knitters and weavers that produce yarn and/or fabric; Nylon, which sells nylon-based products to knitters and weavers that produce fabric for the apparel and hosiery markets; and Brazil and Asia, which sells polyester-based products to knitters that produce fabric for the apparel markets in South America and in Asia.

Verrica Pharmaceuticals is a dermatology therapeutics company focused on the development and commercialization of treatments for people living with skin diseases. The company's primary product candidate, VP-102, is a proprietary drug-device combination of its topical solution of cantharidin, a naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is initially developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. In addition, the company is also developing VP-102 for the treatment of external genital warts.